GB201709076D0 - Parp inhibitors for use in methods of treating cancer - Google Patents

Parp inhibitors for use in methods of treating cancer

Info

Publication number
GB201709076D0
GB201709076D0 GBGB1709076.2A GB201709076A GB201709076D0 GB 201709076 D0 GB201709076 D0 GB 201709076D0 GB 201709076 A GB201709076 A GB 201709076A GB 201709076 D0 GB201709076 D0 GB 201709076D0
Authority
GB
United Kingdom
Prior art keywords
methods
treating cancer
parp inhibitors
parp
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1709076.2A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Breast Cancer Now
Institute of Cancer Research
Original Assignee
Breast Cancer Now
Institute of Cancer Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Breast Cancer Now, Institute of Cancer Research filed Critical Breast Cancer Now
Priority to GBGB1709076.2A priority Critical patent/GB201709076D0/en
Publication of GB201709076D0 publication Critical patent/GB201709076D0/en
Priority to PCT/EP2018/064873 priority patent/WO2018224536A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB1709076.2A 2017-06-07 2017-06-07 Parp inhibitors for use in methods of treating cancer Ceased GB201709076D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB1709076.2A GB201709076D0 (en) 2017-06-07 2017-06-07 Parp inhibitors for use in methods of treating cancer
PCT/EP2018/064873 WO2018224536A1 (en) 2017-06-07 2018-06-06 Parp inhibitors for use in treating cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1709076.2A GB201709076D0 (en) 2017-06-07 2017-06-07 Parp inhibitors for use in methods of treating cancer

Publications (1)

Publication Number Publication Date
GB201709076D0 true GB201709076D0 (en) 2017-07-19

Family

ID=59349931

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1709076.2A Ceased GB201709076D0 (en) 2017-06-07 2017-06-07 Parp inhibitors for use in methods of treating cancer

Country Status (2)

Country Link
GB (1) GB201709076D0 (en)
WO (1) WO2018224536A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113035272B (en) * 2021-03-08 2023-09-05 深圳市新合生物医疗科技有限公司 Method and device for obtaining immunotherapeutic new antigen based on intein cell variation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101370497B (en) * 2006-01-17 2010-11-17 雅培制药有限公司 Combination product with PARP inhibitors and cell toxin and its uses
US20120035244A1 (en) * 2010-07-29 2012-02-09 The Regents Of The University Of Michigan Parp1 targeted therapy
WO2014152330A1 (en) * 2013-03-15 2014-09-25 Stc.Unm Arsenic-based treatment of cancers and inflammatory disorders
US11168369B2 (en) * 2014-11-25 2021-11-09 The Brigham And Women's Hospital, Inc. Method of identifying and treating a person having a predisposition to or afflicted with a cardiometabolic disease
DK3594343T3 (en) * 2015-07-23 2021-06-28 Inst Curie USE OF A COMBINATION OF DBAIT MOLECULE AND PARP INHIBITORS FOR CANCER OF CANCER
PT3337467T (en) * 2015-08-20 2021-01-25 Ipsen Biopharm Ltd Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment

Also Published As

Publication number Publication date
WO2018224536A1 (en) 2018-12-13

Similar Documents

Publication Publication Date Title
HK1245677A1 (en) Heterocyclic itk inhibitors for treating inflammation and cancer
IL249658A0 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
HK1249524A1 (en) Immune-checkpoint inhibitors for use in the treatment of blood-borne cancers
IL255189B2 (en) A combination of rad1901 and a cdk4/6 inhibitor for use in treating cancer
IL284199A (en) Csf1r inhibitors for use in treating cancer
IL284324A (en) Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer
IL284326A (en) Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer
IL266182A (en) Farnesyltransferase inhibitors for use in methods of treating cancer
HK1248281B (en) Use of a combination of dbait molecule and parp inhibitors to treat cancer
IL274198A (en) Use of nox inhibitors for treatment of cancer
IL268722A (en) Methods of treating cancer with farnesyltransferase inhibitors
GB201709076D0 (en) Parp inhibitors for use in methods of treating cancer
IL272473A (en) Methods of treating cancer with farnesyltransferase inhibitors
HRP20191391T1 (en) Use of a combination of dbait molecule and parp inhibitors to treat cancer
PL2999789T3 (en) Method for selection of hdis3 pin domain inhibitors and use of hdis3 pin domain inhibitors for cancer treatment
GB201418640D0 (en) Agents and methods for treatment of cancer

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)